{"filing":{"accession_number":"0001664710-26-000059","cik":"0001664710","ticker":"KROS","company_name":"Keros Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-29","primary_document":"kros-20260929.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000059/kros-20260929.htm"},"events":[{"id":35613,"run_id":32810,"accession_number":"0001664710-26-000059","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Keros announced receipt of a $20 million development milestone payment from Takeda following first-patient dosing in the ELRiSE MF Phase 3 trial for elritercept. This represents a material operational and financial milestone in the company's partnership with Takeda (which included a $200 million upfront payment in February 2025 and potential milestone payments exceeding $1.1 billion). While the payment has financial implications, the core disclosure centers on a clinical development milestone—the initiation of a Phase 3 trial—which is an operational/strategic event rather than a discrete financial transaction like debt issuance or dividend distribution. The company also plans to distribute 25% of net proceeds to stockholders, but the primary event is the milestone achievement and payment announcement.","company_name":"Keros Therapeutics, Inc.","ticker":"KROS","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39729,"accession_number":"0001664710-26-000059","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Keros announced receipt of a $20 million development milestone payment from Takeda following first-patient dosing in the ELRiSE MF Phase 3 trial for elritercept. This represents a material operational and financial milestone in the company's partnership with Takeda (which included a $200 million upfront payment in February 2025 and potential milestone payments exceeding $1.1 billion). While the payment has financial implications, the core disclosure centers on a clinical development milestone—the initiation of a Phase 3 trial—which is an operational/strategic event rather than a discrete financial transaction like debt issuance or dividend distribution. The company also plans to distribute 25% of net proceeds to stockholders, but the primary event is the milestone achievement and payment announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T12:03:44.727080+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39729,"accession_number":"0001664710-26-000059","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Keros announced receipt of a $20 million development milestone payment from Takeda following first-patient dosing in the ELRiSE MF Phase 3 trial for elritercept. This represents a material operational and financial milestone in the company's partnership with Takeda (which included a $200 million upfront payment in February 2025 and potential milestone payments exceeding $1.1 billion). While the payment has financial implications, the core disclosure centers on a clinical development milestone—the initiation of a Phase 3 trial—which is an operational/strategic event rather than a discrete financial transaction like debt issuance or dividend distribution. The company also plans to distribute 25% of net proceeds to stockholders, but the primary event is the milestone achievement and payment announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T12:03:44.727080+00:00","company_name":"Keros Therapeutics, Inc.","ticker":"KROS","filing_date":"2026-09-29"}]}